May and Baker H1 2026
May and Baker is the third largest pharmaceutical company by revenue on the NGX. Here is a look at its H1 2026 earnings and where i feel the stock should be trading at in the mid to long term.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.